Budesonide/salmeterol

Drug Profile

Budesonide/salmeterol

Alternative Names: Budesonide/salmeterol xinafoate; Labazenit; Salmeterol/budesonide

Latest Information Update: 16 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratoires SMB
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Pregnenediones; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 16 Feb 2016 No development reported - Preregistration for Asthma in European Union (Inhalation)
  • 21 Mar 2013 Preregistration for Asthma in European Union (Inhalation) before March 2013
  • 21 Mar 2013 The Committee for Medicinal Products for Human Use of the EMA adopts a negative opinion on marketing authorisation for budesonide/salmeterol for Asthma in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top